Seres announces new translational biomarker results from SER-155 Phase 1b study
Seres Therapeutics (MCRB) announced new translational biomarker results for exploratory endpoints from its SER-155 Phase 1b ...
First of its kind gene therapy model offers hope for X-linked sideroblastic anemia treatment
The sole potential cure for XLSA is currently an allogenic stem cell transplant, which is only an option for a limited number ...
pharmaphorum7y
Cellectis' ‘off the shelf’ CAR-T ready for trials
Off the shelf or allogenic CAR-Ts promise to open up what could be a faster and cheaper way to treat patients with the groundbreaking immunotherapy. The company has already licensed its first ...
Hosted on MSN11d
First Aussie doses bring Imugene major step closer to 'quicker, cheaper' non-Hodgkin’s lymphoma care
Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its ...
expresshealthcare4d
SunAct Cancer Institute and CytoMed begin phase 2 trials for Gamma Delta T-cell therapy
SunAct Cancer Institute has announced the commencement of Phase 2 clinical trials for Gamma Delta (gd) T-cell therapy, a ...